Search research articles
Contact Us
Filters
Showing results (101-110 of 158) with videos related to
Page
of 16
Sort By:
Investigational New Drugs
|
February 19, 2008
A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas
Steven Attia, Jill Kolesar, Michelle R Mahoney, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|
May 20, 2015
Potential cytochrome P-450 drug-drug interactions in adults with metastatic solid tumors and effect on eligibility for Phase I clinical trials
Kari B Wisinski, Colby A Cantu, Jens Eickhoff, et al.
Cancer Chemotherapy and Pharmacology
|
August 30, 2014
Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network
Natalie Callander, Stephanie Markovina, Jens Eickhoff, et al.
Radiology and Oncology
|
July 30, 2020
[18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab
Damijan Valentinuzzi, Martina Vrankar, Nina Boc, et al.
The Oncologist
|
June 3, 2011
A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma
Tabraiz A Mohammed, Kyle D Holen, Renata Jaskula-Sztul, et al.
Cancer Chemotherapy and Pharmacology
|
March 7, 2008
A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer
Noelle K LoConte, James P Thomas, Dona Alberti, et al.
JAMA Health Forum
|
May 15, 2026
Mapping Meaningful Populations of Children With Special Health Care Needs
Amanda K Gatewood, Makenzie Morgen, Jens Eickhoff, et al.
Radiation Research
|
November 19, 2019
Impact of the PrC-210 Radioprotector Molecule on Cancer Deaths in p53-Deficient Mice
William E Fahl, Frank Jermusek, Thomas Guerin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 3, 2008
A phase I pharmacokinetic and pharmacodynamic correlative study of the antisense Bcl-2 oligonucleotide g3139, in combination with carboplatin and paclitaxel, in patients with advanced solid tumors
Glenn Liu, Jill Kolesar, Douglas G McNeel, et al.
Cancer Immunology, Immunotherapy : CII
|
June 9, 2012
Phase II trial of hu14.18-IL2 for patients with metastatic melanoma
Mark R Albertini, Jacquelyn A Hank, Brian Gadbaw, et al.
Page
of 16
Search research articles
Search
Showing results (101-110 of 158) with videos related to
Sort By:
Page
of 16
Investigational New Drugs
|
February 19, 2008
A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas
Steven Attia, Jill Kolesar, Michelle R Mahoney, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|
May 20, 2015
Potential cytochrome P-450 drug-drug interactions in adults with metastatic solid tumors and effect on eligibility for Phase I clinical trials
Kari B Wisinski, Colby A Cantu, Jens Eickhoff, et al.
Cancer Chemotherapy and Pharmacology
|
August 30, 2014
Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network
Natalie Callander, Stephanie Markovina, Jens Eickhoff, et al.
Radiology and Oncology
|
July 30, 2020
[18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab
Damijan Valentinuzzi, Martina Vrankar, Nina Boc, et al.
The Oncologist
|
June 3, 2011
A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma
Tabraiz A Mohammed, Kyle D Holen, Renata Jaskula-Sztul, et al.
Cancer Chemotherapy and Pharmacology
|
March 7, 2008
A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer
Noelle K LoConte, James P Thomas, Dona Alberti, et al.
JAMA Health Forum
|
May 15, 2026
Mapping Meaningful Populations of Children With Special Health Care Needs
Amanda K Gatewood, Makenzie Morgen, Jens Eickhoff, et al.
Radiation Research
|
November 19, 2019
Impact of the PrC-210 Radioprotector Molecule on Cancer Deaths in p53-Deficient Mice
William E Fahl, Frank Jermusek, Thomas Guerin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 3, 2008
A phase I pharmacokinetic and pharmacodynamic correlative study of the antisense Bcl-2 oligonucleotide g3139, in combination with carboplatin and paclitaxel, in patients with advanced solid tumors
Glenn Liu, Jill Kolesar, Douglas G McNeel, et al.
Cancer Immunology, Immunotherapy : CII
|
June 9, 2012
Phase II trial of hu14.18-IL2 for patients with metastatic melanoma
Mark R Albertini, Jacquelyn A Hank, Brian Gadbaw, et al.
Page
of 16